Kura Oncology Stock Earnings Reports
Kura Oncology Earnings Calls
Release date | May 01, 2025 |
EPS estimate | -$0.510 |
EPS actual | - |
Revenue estimate | 39.076M |
Revenue actual | - |
Expected change | +/- 6.76% |
Release date | Feb 26, 2025 |
EPS estimate | -$0.650 |
EPS actual | -$0.220 |
EPS Surprise | 66.15% |
Revenue estimate | 57.962M |
Revenue actual | 53.883M |
Revenue Surprise | -7.04% |
Release date | Nov 07, 2024 |
EPS estimate | -$0.640 |
EPS actual | -$0.630 |
EPS Surprise | 1.56% |
Revenue estimate | 57.962M |
Revenue actual | - |
Release date | Aug 08, 2024 |
EPS estimate | -$0.630 |
EPS actual | -$0.590 |
EPS Surprise | 6.35% |
Revenue estimate | - |
Revenue actual | - |
Last 4 Quarters for Kura Oncology
Below you can see how KURA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Release date | Aug 08, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $19.12 |
EPS estimate | -$0.630 |
EPS actual | -$0.590 |
EPS surprise | 6.35% |
Date | Price |
---|---|
Aug 02, 2024 | $19.50 |
Aug 05, 2024 | $18.86 |
Aug 06, 2024 | $19.14 |
Aug 07, 2024 | $18.57 |
Aug 08, 2024 | $19.12 |
Aug 09, 2024 | $18.97 |
Aug 12, 2024 | $18.98 |
Aug 13, 2024 | $19.03 |
Aug 14, 2024 | $19.04 |
4 days before | -1.95% |
4 days after | -0.418% |
On release day | -0.785% |
Change in period | -2.36% |
Release date | Nov 07, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $17.77 |
EPS estimate | -$0.640 |
EPS actual | -$0.630 |
EPS surprise | 1.56% |
Date | Price |
---|---|
Nov 01, 2024 | $16.88 |
Nov 04, 2024 | $17.81 |
Nov 05, 2024 | $17.52 |
Nov 06, 2024 | $17.84 |
Nov 07, 2024 | $17.77 |
Nov 08, 2024 | $17.68 |
Nov 11, 2024 | $17.56 |
Nov 12, 2024 | $18.57 |
Nov 13, 2024 | $17.75 |
4 days before | 5.27% |
4 days after | -0.113% |
On release day | -0.506% |
Change in period | 5.15% |
Release date | Feb 26, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $7.77 |
EPS estimate | -$0.650 |
EPS actual | -$0.220 |
EPS surprise | 66.15% |
Date | Price |
---|---|
Feb 20, 2025 | $8.15 |
Feb 21, 2025 | $8.25 |
Feb 24, 2025 | $7.88 |
Feb 25, 2025 | $7.88 |
Feb 26, 2025 | $7.77 |
Feb 27, 2025 | $7.65 |
Feb 28, 2025 | $7.71 |
Mar 03, 2025 | $7.25 |
Mar 04, 2025 | $7.33 |
4 days before | -4.66% |
4 days after | -5.66% |
On release day | -1.54% |
Change in period | -10.06% |
Release date | May 01, 2025 |
Fiscal end date | Mar 30, 2025 |
Price on release | - |
EPS estimate | -$0.510 |
EPS actual | - |
Date | Price |
---|---|
Apr 16, 2025 | $5.75 |
Apr 17, 2025 | $5.90 |
Apr 21, 2025 | $6.18 |
Apr 22, 2025 | $6.31 |
Apr 23, 2025 | $6.37 |
Kura Oncology Earnings Call Transcript Summary of Q4 2024
Q4 2024
Key Highlights and Developments:
- Ziftomenib Update:
- Kura is preparing to submit its first New Drug Application (NDA) for ziftomenib targeting relapsed/refractory NPM1-mutant Acute Myeloid Leukemia (AML) next quarter.
- The drug has shown promising clinical activity in the KOMET-001 Phase 2 trial, successfully meeting primary endpoints with a 20-30% complete response (CR) rate. Data from this trial will be presented at the upcoming ASCO conference.
- Kura has achieved alignment with the FDA and EMA on regulatory pathways that could facilitate accelerated approval in both intensive and non-intensive frontline settings.
- Top-line results for the intensive chemotherapy cohort (KOMET-017-IC) are anticipated in 2028.
- Market Opportunity:
- The U.S. market for menin inhibitors in frontline AML is projected to exceed $7 billion annually, underscoring the transformative potential of ziftomenib, particularly considering the high unmet need in AML treatments.
- Pipeline and Strategic Initiatives:
- Kura is advancing other product candidates, including KOMET-015, which will evaluate ziftomenib in combination with imatinib for gastrointestinal stromal tumors (GIST), expected to initiate in the first half of 2025.
- The company is focusing on its farnesyl transferase inhibitor (FTI) programs, particularly KO-2806, which could serve as a companion therapy in combination with various targeted therapies for solid tumors.
- Financial Overview:
- Q4 2024 collaboration revenue was $53.9 million from the partnership with Kyowa Kirin, compared to none the previous year.
- R&D expenses increased to $52.3 million, while general and administrative expenses were $24.1 million.
- Net loss for Q4 2024 was $19.2 million, significantly reduced from $42.8 million in the previous year.
- As of December 31, 2024, cash reserves totaled $727.4 million, supporting operations through 2027.
- Clinical Development Outlook:
- Upcoming milestones include presenting updates at major medical conferences and results from multiple ongoing trials throughout 2025, enhancing the company's position in AML and solid tumors.
- Kura is actively exploring partnerships to leverage its compounds in additional therapeutic areas like diabetes, although it remains focused on oncology.
- Regulatory Engagement and Strategy:
- Kura's interactions with the FDA regarding MRD-negative CR as a surrogate endpoint have been constructive, minimizing concerns about potential disruptions at the agency due to staffing changes.
Conclusion:
Kura Oncology is well-positioned for significant advancements in its pipeline, particularly with ziftomenib, and is poised for potential accelerated approval and commercialization in AML. The company's strong financial position and strategic collaborations are expected to facilitate ongoing development and enhance shareholder value in the forthcoming years. Investors should monitor upcoming trial results, regulatory developments, and market conditions closely as Kura continues to drive its innovative oncology therapies forward.